Memorandum of Understanding Between the National Cancer Institute and the Food and Drug Administration, 19534-19539 [07-1921]

Download as PDF 19534 Federal Register / Vol. 72, No. 74 / Wednesday, April 18, 2007 / Notices pwalker on PROD1PC71 with NOTICES address, company phone number, and email address. You will receive a confirmation within 2 business days. We also will accept walk-in registration at the meeting site, but space is limited, and we will close registration when maximum seating capacity (approximately 100) is reached. We will try to accommodate all persons who wish to make a presentation. The time allotted for presentations may depend on the number of persons who wish to speak. Additionally, regardless of whether you wish to make a presentation or simply attend the meeting, please notify us if you need any special accommodations (such as wheelchair access or a sign language interpreter). If you would like to submit comments regarding these proposed recommendations, please send your comments to the Division of Dockets Management (see ADDRESSES). Submit a single copy of electronic comments or two paper copies of any written comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Submit your comments no later than May 18, 2007. VerDate Aug<31>2005 17:04 Apr 17, 2007 Jkt 211001 C. Will Meeting Transcripts Be Available? We will prepare a meeting transcript and make it available on our Web site (https://www.fda.gov) after the meeting. We anticipate that transcripts will be available approximately 30 working days after the meeting. The transcript will also be available for public examination at the Division of Dockets Management (HFA–305), 5630 Fishers Lane, rm. 1061, Rockville, MD 20857, between 9 a.m. and 4 p.m. Monday through Friday. Dated: April 12, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 07–1919 Filed 4–16–07; 1:52 pm] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [FDA 225–07–4301] Memorandum of Understanding Between the National Cancer Institute and the Food and Drug Administration AGENCY: Food and Drug Administration, HHS. ACTION: PO 00000 Notice. Frm 00074 Fmt 4703 SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS). The purpose of this MOU is to establish a formal collaboration between FDA and NCI regarding the creation of a common standards-based data repository to facilitate the electronic exchange and analysis of data from research studies on investigational drugs in a fully secure manner. The agreement became effective March 2, 2007. FOR FURTHER INFORMATION CONTACT: Randy Levin, Center for Drug Evaluation Research (HF–18), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7784 email: randy.levin@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the Federal Register, the agency is publishing notice of this MOU. DATES: Dated: April 5, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. BILLING CODE 4160–01–S Sfmt 4703 E:\FR\FM\18APN1.SGM 18APN1 VerDate Aug<31>2005 17:04 Apr 17, 2007 Jkt 211001 PO 00000 Frm 00075 Fmt 4703 Sfmt 4725 E:\FR\FM\18APN1.SGM 18APN1 19535 EN18AP07.000</GPH> pwalker on PROD1PC71 with NOTICES Federal Register / Vol. 72, No. 74 / Wednesday, April 18, 2007 / Notices VerDate Aug<31>2005 Federal Register / Vol. 72, No. 74 / Wednesday, April 18, 2007 / Notices 17:04 Apr 17, 2007 Jkt 211001 PO 00000 Frm 00076 Fmt 4703 Sfmt 4725 E:\FR\FM\18APN1.SGM 18APN1 EN18AP07.001</GPH> pwalker on PROD1PC71 with NOTICES 19536 VerDate Aug<31>2005 17:04 Apr 17, 2007 Jkt 211001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4725 E:\FR\FM\18APN1.SGM 18APN1 19537 EN18AP07.002</GPH> pwalker on PROD1PC71 with NOTICES Federal Register / Vol. 72, No. 74 / Wednesday, April 18, 2007 / Notices VerDate Aug<31>2005 Federal Register / Vol. 72, No. 74 / Wednesday, April 18, 2007 / Notices 18:01 Apr 17, 2007 Jkt 211001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4725 E:\FR\FM\18APN1.SGM 18APN1 EN18AP07.003</GPH> pwalker on PROD1PC71 with NOTICES 19538 19539 [FR Doc. 07–1921 Filed 4–17–07; 8:45 am] BILLING CODE 4160–01–C VerDate Aug<31>2005 18:20 Apr 17, 2007 Jkt 211001 PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 E:\FR\FM\18APN1.SGM 18APN1 EN18AP07.004</GPH> pwalker on PROD1PC71 with NOTICES Federal Register / Vol. 72, No. 74 / Wednesday, April 18, 2007 / Notices

Agencies

[Federal Register Volume 72, Number 74 (Wednesday, April 18, 2007)]
[Notices]
[Pages 19534-19539]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1921]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA 225-07-4301]


Memorandum of Understanding Between the National Cancer Institute 
and the Food and Drug Administration

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is providing notice of 
a memorandum of understanding (MOU) between FDA and the National Cancer 
Institute (NCI), part of the National Institutes of Health (NIH) of the 
Department of Health and Human Services (DHHS). The purpose of this MOU 
is to establish a formal collaboration between FDA and NCI regarding 
the creation of a common standards-based data repository to facilitate 
the electronic exchange and analysis of data from research studies on 
investigational drugs in a fully secure manner.

DATES: The agreement became effective March 2, 2007.

FOR FURTHER INFORMATION CONTACT: Randy Levin, Center for Drug 
Evaluation Research (HF-18), Food and Drug Administration, 5600 Fishers 
Lane, Rockville, MD 20857, 301-827-7784 e-mail: 
randy.levin@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which 
states that all written agreements and MOUs between FDA and others 
shall be published in the Federal Register, the agency is publishing 
notice of this MOU.

    Dated: April 5, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
BILLING CODE 4160-01-S

[[Page 19535]]

[GRAPHIC] [TIFF OMITTED] TN18AP07.000


[[Page 19536]]


[GRAPHIC] [TIFF OMITTED] TN18AP07.001


[[Page 19537]]


[GRAPHIC] [TIFF OMITTED] TN18AP07.002


[[Page 19538]]


[GRAPHIC] [TIFF OMITTED] TN18AP07.003


[[Page 19539]]


[GRAPHIC] [TIFF OMITTED] TN18AP07.004

[FR Doc. 07-1921 Filed 4-17-07; 8:45 am]
BILLING CODE 4160-01-C
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.